Table 2.
Vitamin A group | Placebo group | Risk per 1000 in vitamin A group | Risk per 1000 in placebo group | Risk difference per 1000 (95% CI) | Risk ratio (95% CI) | p value | |||
---|---|---|---|---|---|---|---|---|---|
|
|
||||||||
Events | Newborns | Events | Newborns | ||||||
Mortality at 6 months (n=30 892)
| |||||||||
Overall | 407 | 15 428 | 372 | 15 464 | 26·38 | 24·06 | 2·32 (−1·17 to 5·82) | 1·10 (0·95 to 1·26) | 0·193 |
Boys | 233 | 8135 | 215 | 8070 | 28·64 | 26·64 | 2·00 (−3·05 to 7·05) | 1·08 (0·90 to 1·29) | 0·438 |
Girls | 174 | 7291 | 157 | 7392 | 23·87 | 21·24 | 2·63 (−2·18 to 7·43) | 1·12 (0·91 to 1·39) | 0·284 |
Interaction with sex | ·· | ·· | ·· | ·· | ·· | ·· | ·· | ·· | 0·760 |
| |||||||||
Neonatal mortality (n=31 387)
| |||||||||
Overall | 213 | 15 677 | 206 | 15 710 | 13·59 | 13·11 | 0·47 (−2·07 to 3·01) | 1·04 (0·86 to 1·25) | 0·714 |
Boys | 124 | 8273 | 124 | 8198 | 14·99 | 15·13 | −0·14 (−3·86 to 3·58) | 0·99 (0·77 to 1·27) | 0·942 |
Girls | 89 | 7402 | 82 | 7510 | 12·02 | 10·92 | 1·11 (−2·31 to 4·52) | 1·10 (0·82 to 1·48) | 0·526 |
Interaction with sex | ·· | ·· | ·· | ·· | ·· | ·· | ·· | ·· | 0·594 |
| |||||||||
Mortality at 12 months (n=29 435)
| |||||||||
Overall | 566 | 14 686 | 546 | 14 749 | 39 | 37 | 1·52 (−2·84 to 5·88) | 1·04 (0·93 to 1·17) | 0·494 |
Boys | 312 | 7745 | 324 | 7713 | 40 | 42 | −1·72 (−7·99 to 4·54) | 0·96 (0·82 to 1·12) | 0·590 |
Girls | 254 | 6939 | 222 | 7034 | 37 | 32 | 5·04 (−0·97 to 11·06) | 1·16 (0·97 to 1·38) | 0·100 |
Interaction with sex | ·· | ·· | ·· | ·· | ·· | ·· | ·· | ·· | 0·111 |
| |||||||||
Hospital admission up to 6 months (n=30 895)
| |||||||||
Overall | 332 | 15 429 | 303 | 15 466 | 21·52 | 19·59 | 1·93 (−1·24 to 5·09) | 1·10 (0·94 to 1·28) | 0·233 |
Boys | 194 | 8135 | 166 | 8072 | 23·85 | 20·56 | 3·28 (−1·25 to 7·82) | 1·16 (0·94 to 1·42) | 0·156 |
Girls | 138 | 7292 | 137 | 7392 | 18·92 | 18·53 | 0·39 (−3·99 to 4·78) | 1·02 (0·81 to 1·29) | 0·861 |
Interaction with sex | ·· | ·· | ·· | ·· | ·· | ·· | ·· | ·· | 0·422 |
All event rates given over participants not lost to follow-up before end of risk period.